MICROPORT NEUROTECH
MicroPort NeuroTech is a medical device company that specializes in neurological intervention. It develops innovative products that deliver safe, effective, and accurate solutions for patients with cerebrovascular diseases. MicroPort NeuroTech's unique products include WILLIS Intracranial Stent Graft System, APOLLO Intracranial Stent System, and Tubridge Vascular Reconstruction Device for treatments. The products promote therapeutic options adapted to specific needs. MicroPort NeuroTech was founded on May 2012 and is based in Shanghai, China.
MICROPORT NEUROTECH
Industry:
Health Diagnostics Medical Device Neuroscience Therapeutics
Founded:
2012-05-01
Address:
Shanghai, Shanghai, China
Country:
China
Website Url:
http://www.medneurotech.com
Status:
Active
Contact:
(86) (21) 38954600-3200
Email Addresses:
[email protected]
Total Funding:
150 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Google Tag Manager Global Site Tag Mobile Non Scaleable Content Nginx Euro DigiCert SSL Google Analytics 4
Similar Organizations
Cara Care
Cara Care is a digital gut health platform that offers an app-based treatment to help patients with chronic gastrointestinal problems.
SceneRay
SceneRay is a medical device company dedicated to the design, Development, and distribution of neuromodulation devices.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Employees Featured
Investors List
CICC Healthcare Investment Fund
CICC Healthcare Investment Fund investment in Venture Round - MicroPort NeuroTech
Huayi Capital
Huayi Capital investment in Venture Round - MicroPort NeuroTech
Official Site Inspections
http://www.medneurotech.com Semrush global rank: 7.26 M Semrush visits lastest month: 548
- Host name: 47.101.140.217
- IP address: 47.101.140.217
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "MicroPort NeuroTech"
Investor Relations | MicroPort NeuroTech
MicroPort NeuroTech (02172.HK) was founded in 2012 and headquartered in Shanghai Zhangjiang Hi-Tech Park. After many years of development, we have established a …See details»
Dr. Chang Zhaohua | MicroPort NeuroTech - ir.medneurotech.com
Dr. Chang Zhaohua (常兆华), the chairman and a non-executive Director of our company. He is primarily responsible for overseeing the management and operations of our Group. Dr. Chang, …See details»
MicroPort® NeuroTech（Shanghai）Co., Ltd.
After nearly 10 years of development, MicroPort® NeuroTech has built a talented team that is highly responsive to clinical needs and strong in innovation and R&D. MicroPort® NeuroTech owns more than 100 domestic and international …See details»
Financial Reports | MicroPort NeuroTech - ir.medneurotech.com
Sep 27, 2024 · 1661 Zhangdong Road, Zhangjiang High-tech Park, Pudong New District, Shanghai, PRCSee details»
MicroPort NeuroTech - Crunchbase Company Profile
MicroPort NeuroTech is a medical device company that specializes in neurological intervention. It develops innovative products that deliver safe, …See details»
MicroPort NeuroTech™ Debuts on Main Board of HKEX
Jul 15, 2022 · As committed to becoming a global leader in the neuro-interventional medical device market, MicroPort NeuroTech™ has established a series of localized sale …See details»
Coil Embolization System Approval in Japan | News | MicroPort
Tokyo, Japan, 27 August 2022 – MicroPort Neurotech Limited (“MicroPort NeuroTech™”), a pioneering Chinese company in the field of neurovascular interventional treatment, today …See details»
Blueprint Neurotech
Sep 9, 2024 · Projects to facilitate the deployment of long-term therapy for those with persistent neurologic deficits, including technologies for home-based interventions, that address motor, …See details»
MicroPort NeuroTech Americas | LinkedIn
At #MicroPort, integrity is woven into the fabric of everything we do. We strive to meet the highest ethical standards to provide innovative solutions for #BetterHealth while conducting ourselves...See details»
投资者关系 | 微创神通 - ir.medneurotech.com
经过多年发展，公司已建立全面的脑卒中介入治疗产品线，覆盖出血性脑卒中、动脉粥样硬化狭窄和急性缺血性脑卒中三大神经血管疾病领域，提供脑血管疾病治疗全解方案。 截至2023年8月 …See details»
微创神通医疗科技（上海）有限公司
微创神通医疗科技（上海）有限公司的使命是为治疗脑血管疾病提供可及性真善美全医疗方案，建设一个以人为本的新兴高科技医疗超级集群，经过多年发展，公司已建立全面的脑卒中介入治 …See details»
MicroPort® NeuroTech™ Issues Positive Profit Alert for 2023 …
Jan 15, 2024 · MicroPort® NeuroTech™ has issued a positive profit alert regarding its 2023 annual performance on the Hong Kong Stock Exchange.See details»
MicroPort NeuroTech - Overview, News & Similar companies
MicroPort NeuroTech contact info: Phone number: +86 2120960693 Website: www.medneurotech.com What does MicroPort NeuroTech do? MicroPort NeuroTech …See details»
Presentation Materials | MicroPort NeuroTech
Aug 31, 2023 · 1661 Zhangdong Road, Zhangjiang High-tech Park, Pudong New District, Shanghai, PRCSee details»
MDSAP Certificate Award | News & Events |MicroPort
Mar 28, 2023 · It allows an MDSAP-recognized auditing organization to conduct a single audit of a medical device manufacturer that satisfies the regulatory requirements of all five countries. …See details»
2024報告 2024REPORT - ir.medneurotech.com
4 MICROPORT NEUROSCIENTIFIC CORPORATION Definitions (Continued) “share(s)” ordinary share(s) of the Company “Shareholder(s)” holder(s) of the share(s) “Stock Exchange” The …See details»
NeuroTech Named 2020 High-Tech Giant | News | MicroPort
Shanghai, China, November 23, 2020 — Shanghai MicroPort NeuroTech Co., Ltd. (“MicroPort NeuroTech”) was recently named Shanghai High-tech “Little Giant” Enterprise by the …See details»
edoc.medneurotech.com - AnyShare Express
Edoc.medneurotech.com - AnyShare ExpressSee details»
MicroPort NeuroTech™ NUMEN®’s Research Results Published in …
Shanghai, China, 08 August 2023 — The research results of the NUMEN™ Coil Embolization System (NUMEN™) developed by MicroPort NeuroTech (Shanghai) Co., Ltd.（MicroPort …See details»
MicroPort® NeuroTech™ Announces Publication of Safety Study …
Apr 2, 2024 · Led by Professor Jianmin Liu from the Cerebrovascular Disease Center at Changhai Hospital, the study involved collaboration with prominent neurointervention centers across China.See details»